KEYNOTE-716: Adjuvant pembrolizumab prolongs recurrence-free survival in resected stage II melanoma

Share :
Published: 18 Sep 2021
Views: 964
Dr Jason Luke - UPMC Hillman Cancer Center, Pittsburgh, USA

Dr Jason Luke talks to ecancer for the ESMO 2021 meeting about the overall survival results from the phase III KEYNOTE-716 study.

This study looked at the use of pembrolizumab versus placebo after complete resection of high-risk stage II melanoma.

Dr Luke explains that this was an international randomised placebo-controlled double-blind study where patients were split 1-1 between pembrolizumab and placebo.

He reports that patients who received pembrolizumab experienced a 35% reduction in the risk of recurrence and also the number of distant metastasis recurrences.

Read more about this study here.

ecancer's filming has been kindly supported by Amgen through the ecancer Global Foundation. ecancer is editorially independent and there is no influence over content.